Toripalimab
KY2025-352
Phase 2 small_molecule active
Quick answer
Toripalimab for Urinary Bladder Neoplasms is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Urinary Bladder Neoplasms
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active